Innovating Works
PAH-Advance: PAH-ADVANCE: Accelerating the Clinical Path of NTP42, a disease-modifying drug that will disrupt the... ATXA THERAPEUTICS LTD tramitó un HORIZON EUROPE: HORIZON-EIC-2022-ACCELERATOR-01 ATXA Therapeutics has developed NTP42, a disruptive new drug for pulmonary arterial hypertension (PAH) and related cardiopulmonary (heart &...
2022-12-19 - 2023-12-31 | Financiado
PAH-HOPE: New hope for the PAH patient A Novel Therapeutic for Pulmonary Arterial Hypertension PAH ATXA THERAPEUTICS LTD tramitó un H2020: H2020-EIC-SMEInst-2018-2020 ATXA Therapeutics Ltd is a company on a mission to offer new hope to patients with pulmonary arterial hypertension (PAH). PAH is a debilitat...
2018-07-17 - 2021-03-31 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.